AIDS Alert Archives – April 1, 2011
April 1, 2011
View Issues
-
ADAPs worst-case scenario arrives with a vengeance
For years HIV experts and advocates have warned that unless federal funding for the AIDS Drug Assistance Program (ADAP) was ramped up significantly then thousands of Americans could be left off the roles and face risks of illness and death without dependable access to antiretroviral therapy (ART). -
Will the safety net hold? New partnerships help
With unprecedented numbers of HIV patients pushed onto waiting lists to receive antiretroviral (ART) drugs from AIDS Drug Assistance Programs (ADAPs), the bottom rung safety nets are barely holding, experts say. -
Certain cancers increase in pts on long-term ART
HIV clinicians are seeing increasing numbers of patients who are developing cancers associated with infectious agents, particularly in the areas of the oropharynx and genitals, researchers say. -
Time to boost uptake of HPV vaccine in men
While the human papillomavirus (HPV) vaccine has been approved for use in men, how many are open to receiving it? New research indicates men might be more willing to receive vaccination when they learn the vaccine can prevent cancer. -
Interim guidance for PrEP In MSM
The Centers for Disease Control and Prevention is developing formal guidelines on preexposure prophylaxis (PrEP) to prevent HIV in men who have sex with men (MSM). In the interim, the CDC has issued the following recommendations to guide clinical practice. -
HIV transmission to HCWs virtually eliminated
The once rare but very real risk of occupational HIV transmission continues to fade in the face of a host of prevention measures that include needle safety devices and post-exposure prophylaxis. -
Abstract & Commentary: Higher risk of perinatal HIV transmission in TB mothers
In this study, 783 HIV-infected Indian mother-infant pairs participated in a randomized clinical trial comparing NVP given for 6 weeks vs. single-dose NVP to prevent MTCT of HIV among breast-fed infants. -
FDA Notifications: Genentech issues letter about Fuzeon® co-product
Genentech has issued the following Dear Healthcare Professional letter for users of Fuzeon and certain other injection products: